Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration to Develop Hemophilia Therapies

06-Feb-2007

Wyeth Pharmaceuticals, a division of Wyeth, and Nautilus Biotech in Evry, France, announced the signing of a research collaboration and license agreement to discover and develop novel recombinant Factor IX proteins for the treatment of hemophilia B. These extended half-life proteins will be designed to enhance patient convenience as they will reduce the number and frequency of treatments needed.

As part of the agreement, Nautilus Biotech will apply its proprietary technology to improve the duration of action of recombinant hemophilia B therapy. The Nautilus Biotech technology makes minimal and specific changes to amino acids sequences in order to slow the breakdown of the protein in the body.

Under the terms of this agreement, Wyeth will develop, manufacture and market products derived from the collaborative research. Nautilus Biotech will receive an upfront payment, research and development fees, milestone payments from Wyeth associated with development, regulatory filings and approvals, and royalty payments based on net sales of products.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...